Breaking News Instant updates and real-time market news.

DPLO

Diplomat Pharmacy

$17.44

-0.17 (-0.97%)

, NVS

Novartis

$80.08

0.22 (0.28%)

16:33
05/18/17
05/18
16:33
05/18/17
16:33

Diplomat Pharmacy now dispensing Novartis' Rydapt for acute myeolid leukemia

Diplomat Pharmacy (DPLO) is now dispensing Rydapt, recently approved by the FDA. Rydapt is manufactured by Novartis (NVS) and is approved to treat newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive, as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. The FDA also approved Rydapt to treat aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, and mast cell leukemia.

DPLO

Diplomat Pharmacy

$17.44

-0.17 (-0.97%)

NVS

Novartis

$80.08

0.22 (0.28%)

  • 19

    May

  • 06

    Jun

  • 26

    Jun

DPLO Diplomat Pharmacy
$17.44

-0.17 (-0.97%)

05/09/17
BARD
05/09/17
NO CHANGE
Target $20
BARD
Outperform
Diplomat Pharmacy shares should react positively to 'clean' quarter, says Baird
Baird analyst Eric Coldwell said Diplomat Pharmacy reported its "cleanest and calmest" quarter in a long time and as a result he believes the shares should react positively. He noted the earnings beat, unchanged guidance, and management's enthusiastic comments about upcoming catalysts, including upcoming FDA approvals. Coldwell reiterated his Outperform rating and $20 price target on Diplomat Pharmacy shares.
05/09/17
LEHM
05/09/17
NO CHANGE
Target $20
LEHM
Overweight
Diplomat Pharmacy price target raised to $20 from $17 at Barclays
Barclays analyst Eric Percher raised his price target for Diplomat Pharmacy to $20 citing the "solid" Q1 results and acquisition of WRB Communications. The analyst maintains an Overweight rating on the shares.
03/06/17
BARD
03/06/17
NO CHANGE
Target $20
BARD
Outperform
Significant opportunities ahead for Diplomat Pharmacy, says Baird
Baird analyst Eric Coldwell traveled with Diplomat Pharmacy and now believes there are significant opportunities ahead as its platform remains differentiated and last year reset expectations. Coldwell said crisper execution is required, but he sees a pathway to returning growth in 2018 and beyond. Coldwell reiterated his Outperform rating and $20 price target on Diplomat Pharmacy shares.
03/01/17
BARD
03/01/17
NO CHANGE
Target $20
BARD
Outperform
Diplomat Pharmacy results should satisfy lowered expectations, says Baird
Baird analyst Eric Coldwell noted Diplomat Pharmacy reported Q4 results that were in-line with expectations and provided guidance that is likely ahead of lowered expectations. Coldwell maintained his Outperform rating and $20 price target on Diplomat shares.
NVS Novartis
$80.08

0.22 (0.28%)

05/15/17
LEER
05/15/17
NO CHANGE
LEER
GlaxoSmithKline possible move to buyout Novartis stake makes sense, says Leerink
Leerink analyst Seamus Fernandez is not surprised by the news that GlaxoSmithKline (GSK) may buyout Novartis' (NVS) 36.5% stake in its Consumer Healthcare joint venture through a GBP8B deal sooner rather than later. The analyst believes this buyout could be beneficial as the infusion of additional cash from the buyout could bolster Novartis appetite for large scale M&A, including companies such as AstraZeneca (AZN) whose immune-oncology assets could complement its small-molecule focused oncology portfolio, according to the London Times.
04/21/17
ROTH
04/21/17
NO CHANGE
Target $12
ROTH
Buy
Conatus price target raised to $12 from $4 at Roth Capital
Roth Capital analyst Sa'ar Yaniv raised his price target for Conatus (CNAT) to $12 from $4 following discussions with management, 2016 results, assessment of the competitive cirrhosis space, and clarity from the Novartis (NVS) deal. The analyst believes Conatus' shares are undervalued and reiterates a Buy rating on the stock.
04/18/17
WELS
04/18/17
NO CHANGE
WELS
Allergan partnership a 'promising free option,' says Wells Fargo
Wells Fargo analyst David Maris views Allergan's (AGN) partnership with Novartis (NVS) to conduct a Phase IIb study using its cenicriviroc and Novartis's lead FXR agonist for the treatment of nonalcoholic steatohepatitis as a "promising free option." The deal is a way to maximize Allergan's shots-on-goal in combination NASH treatments, Maris tells investors in a research note. He has an Outperform rating on Allergan shares.
04/05/17
04/05/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AstraZeneca (AZN) downgraded to Neutral from Buy at UBS. 2. Novartis (NVS) downgraded to Market Perform from Outperform at Cowen with analyst Steve Scala saying he believes the company's earnings growth looks below the industry average given the current weakness in Alcon and Entresto's slow rollout. 3. MSG Networks (MSGN) downgraded to Neutral following NY Post report at Macquarie with analyst Tim Nollen citing valuation and maintained its $26 price target. 4. Generac (GNRC) downgraded to Sector Weight from Overweight at KeyBanc with analyst Jeffrey Hammond citing concerns that increased pricing incentives and normalizing storm activity are impacting the growth for the company's Residential home standby business. 5. Amgen (AMGN) downgraded to Hold from Buy at Jefferies with analyst Eun Yang saying she believes upside in the stock will likely be "muted" after her payor poll indicated continuing reimbursement challenges for Repatha, Amgen's PCSK9 inhibitor to treat high cholesterol. Yang also sees a "scarcity of blockbuster potential pipeline products" and feels a transformative acquisition is unlikely. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

INTU

Intuit

$127.16

1.78 (1.42%)

14:49
05/23/17
05/23
14:49
05/23/17
14:49
Options
Intuit options imply 5.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

HON

Honeywell

$131.92

0.08 (0.06%)

14:47
05/23/17
05/23
14:47
05/23/17
14:47
Hot Stocks
Breaking Hot Stocks news story on Honeywell »

Honeywell CEO says some…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

CNQ

Canadian Natural

$31.04

-0.08 (-0.26%)

, RDS.A

Royal Dutch Shell

$55.22

-0.0499 (-0.09%)

14:45
05/23/17
05/23
14:45
05/23/17
14:45
Periodicals
Breaking Periodicals news story on Canadian Natural, Royal Dutch Shell, Royal Dutch Shell »

Shell to sell entire 8.8%…

CNQ

Canadian Natural

$31.04

-0.08 (-0.26%)

RDS.A

Royal Dutch Shell

$55.22

-0.0499 (-0.09%)

RDS.B

Royal Dutch Shell

$56.96

-0.0576 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRE

Sempra Energy

$113.64

0.77 (0.68%)

14:45
05/23/17
05/23
14:45
05/23/17
14:45
Periodicals
CBS LA teases 'shocking' report on Sempra's Aliso Canyon gas leak »

CBS Los Angeles tweeted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Sep

X

U.S. Steel

$20.43

0.96 (4.93%)

14:45
05/23/17
05/23
14:45
05/23/17
14:45
Technical Analysis
Technical Analysis: U.S. Steel breaking out of downtrend, levels to watch »

The stock is rallying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HON

Honeywell

$131.70

-0.14 (-0.11%)

14:42
05/23/17
05/23
14:42
05/23/17
14:42
Hot Stocks
Breaking Hot Stocks news story on Honeywell »

Honeywell CEO says thinks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

X

U.S. Steel

$20.39

0.9169 (4.71%)

14:40
05/23/17
05/23
14:40
05/23/17
14:40
Options
US Steel calls outpace puts nearly 3:1 as shares rally »

US Steel calls outpace…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOMO

Momo

$42.83

-0.75 (-1.72%)

14:39
05/23/17
05/23
14:39
05/23/17
14:39
Downgrade
Momo rating change  »

Momo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

AZO

AutoZone

$596.00

-63.49 (-9.63%)

14:39
05/23/17
05/23
14:39
05/23/17
14:39
Recommendations
AutoZone analyst commentary  »

AutoZone weakness an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

HON

Honeywell

$131.63

-0.21 (-0.16%)

14:37
05/23/17
05/23
14:37
05/23/17
14:37
Hot Stocks
Breaking Hot Stocks news story on Honeywell »

Honeywell CEO says he…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

ALXN

Alexion

$115.42

1.58 (1.39%)

14:31
05/23/17
05/23
14:31
05/23/17
14:31
Recommendations
Alexion analyst commentary  »

Alexion should be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

RBS

RBS

$6.95

0.09 (1.31%)

14:30
05/23/17
05/23
14:30
05/23/17
14:30
Options
Royal Bank of Scotland sees put buying »

Royal Bank of Scotland…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

HON

Honeywell

$131.98

0.14 (0.11%)

14:29
05/23/17
05/23
14:29
05/23/17
14:29
Hot Stocks
Honeywell says spinoff of aerospace is 'intriguing concept' »

This comment was made…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

HON

Honeywell

$132.08

0.235 (0.18%)

14:25
05/23/17
05/23
14:25
05/23/17
14:25
Hot Stocks
Honeywell to shape portfolio changes over next 2-3 years »

Comments are from EPG…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

HLF

Herbalife

$69.44

-4 (-5.45%)

14:21
05/23/17
05/23
14:21
05/23/17
14:21
Technical Analysis
Technical Analysis: Herbalife falls on report China executive departs »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BG

Bunge

$80.28

10.21 (14.57%)

14:20
05/23/17
05/23
14:20
05/23/17
14:20
Options
Newsbots go Bungee jumping this afternoon »

Newsbots go Bungee…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$122.18

0.52 (0.43%)

14:18
05/23/17
05/23
14:18
05/23/17
14:18
Hot Stocks
United Technologies CEO not interested in split »

Speaking at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

MOMO

Momo

$42.83

-0.75 (-1.72%)

14:17
05/23/17
05/23
14:17
05/23/17
14:17
Recommendations
Momo analyst commentary  »

Momo price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

$NSD

NASDAQ Market Internals

14:17
05/23/17
05/23
14:17
05/23/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
05/23/17
05/23
14:16
05/23/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIG

AIG

$61.56

0.175 (0.29%)

14:12
05/23/17
05/23
14:12
05/23/17
14:12
Hot Stocks
A.M. Best affirms AIG credit ratings, removes from under review »

A.M. Best has removed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

BWLD

Buffalo Wild Wings

$150.60

-2 (-1.31%)

14:11
05/23/17
05/23
14:11
05/23/17
14:11
Technical Analysis
Technical Analysis: Buffalo Wild Wings trades at session lows »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HON

Honeywell

$131.96

0.12 (0.09%)

14:11
05/23/17
05/23
14:11
05/23/17
14:11
Earnings
Honeywell backs FY17 EPS view $6.90-$7.10, consensus $7.09 »

Backs FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

HON

Honeywell

$131.98

0.14 (0.11%)

14:08
05/23/17
05/23
14:08
05/23/17
14:08
Earnings
Honeywell backs Q2 EPS view $1.75-$1.80, consensus $1.78 »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

WRB

W. R. Berkley

$67.93

0.26 (0.38%)

14:05
05/23/17
05/23
14:05
05/23/17
14:05
Hot Stocks
Ca. Insurance Commissioner announces $12M settlement with W. R. Berkley »

California Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.